Skip to content

Prognostic Role and Immune Impact of ALKBH1 in Hepatocellular Carcinoma: Insights from Multi-Omics and Spatial Transcriptomics Analysis

Prognostic Role and Immune Impact of ALKBH1 in Hepatocellular Carcinoma: Insights from Multi-Omics and Spatial Transcriptomics Analysis - ALKBH1 as a Prognostic Biomarker and Regulator of Immune Infiltration in Hepatocellular Carcinoma: Insights from Multi-Omics and Spatial Transcriptomics Analyses

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500106522
Enrollment
Unknown
Registered
2025-07-24
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper right abdominal pain or discomfort: Due to the growth of the tumor or the expansion of the liver capsule, patients may experience abdominal pain or discomfort. Jaundice: Impaired liver function or tumor compression on the bile ducts can lead to an increase in bilirubin levels, causing the skin and the whites of the eyes to appear yellow. Weight loss and loss of appetite: These are common s

Interventions

Group with high expression of ALKBH1:None
Group with low expression of ALKBH1:None

Sponsors

The Second Affiliated Hospital of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Human HCC tissue samples were obtained from the Second Affiliated Hospital of Harbin Medical University and were diagnosed as hepatocellular carcinoma with clear pathological results; 2.Clinical information is complete; 3.Tissue samples from liver cancer can be tested; 4.Follow-up information of patients was improved;

Exclusion criteria

Exclusion criteria: (1) Patients with liver lesions (2) Patients lack clinical and follow-up information.

Design outcomes

Primary

MeasureTime frame
Overall Survival Rate;Disease-free Survival Period;Progression-free Survival;

Secondary

MeasureTime frame
ALKBH1 expression level;

Countries

China

Contacts

Public ContactZhongqi Sun

The Second Affiliated Hospital of Harbin Medical University

sunzhongqi2021@163.com+86 451 8666 9470

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026